Iliac Vein Stenting Appears Safe in Office-Based Lab Setting

In HealthDay News
by Healthday

7.36 percent of patients had minor complications, mainly insertion site hematomas; 0.41 percent had major complications

MONDAY, Feb. 7, 2022 (HealthDay News) — Iliac vein stenting seems safe in an office-based laboratory (OBL) setting, with few major complications and minor complications primarily including insertion site hematomas, according to a study published in the January issue of the Journal of Vascular Surgery: Venous and Lymphatic Disorders.

Ishan Satwah, from the Center for Vascular Medicine in Greenbelt, Maryland, and colleagues prospectively collected data in the Center for Vascular Medicine electronic medical record system and examined the safety profile of iliac vein stenting in an OBL setting. The analysis included patient consultations, interventions, and follow-up at one to six weeks. During the procedure, all patients received moderate sedation.

The researchers found that 1,223 iliac vein stents were placed in 1,104 patients between January 2015 and January 2019. There were 90 minor complications (7.36 percent), mainly insertion site hematomas, and five major complications (0.41 percent), including one allergic reaction, one atrial fibrillation episode, one supraventricular tachycardia episode, one chest pain episode, and one acute stent occlusion. None of the complications were related to sedation or acute renal failure, and none of the patients died.

“In the present study, major complications had occurred in 0.41 percent of our patients. This rate suggests that iliac vein stenting in the OBL setting is safer than stenting procedures performed in the hospital setting,” the authors write.

Abstract/Full Text

Copyright © 2021 HealthDay. All rights reserved.